Zometa - Drug Monograph

Introduction

Zometa (zoledronic acid) is a third-generation intravenous bisphosphonate that potently inhibits bone resorption by targeting osteoclast activity. It is primarily used to manage hypercalcemia of malignancy, prevent skeletal-related events in patients with advanced solid tumors or multiple myeloma, and treat osteoporosis. Its high potency and convenient annual or intermittent intravenous dosing distinguish it from oral bisphosphonates and earlier-generation intravenous agents.

Drug Class and Overview

Zoledronic acid belongs to the bisphosphonate class of drugs, specifically the nitrogen-containing aminobisphosphonates. Related agents include pamidronate (second-generation), alendronate, risedronate, and ibandronate. Zoledronic acid is the most potent bisphosphonate in clinical use, approximately 100–850 times more potent than pamidronate on a molar basis. Key distinguishing features include its rapid intravenous administration (15 minutes), high affinity for bone mineral, and prolonged retention in bone, which supports dosing intervals of up to 12 months for osteoporosis.

Mechanism of Action

Zoledronic acid binds with high affinity to hydroxyapatite crystals in bone, particularly at sites of active bone remodeling. Osteoclasts internalize the drug during bone resorption, where it inhibits farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway. This blocks the prenylation of small GTPase proteins (e.g., Ras, Rho, Rac) essential for osteoclast function and survival, leading to osteoclast apoptosis and reduced bone resorption. The resulting clinical effects include decreased bone turnover markers, increased bone mineral density, and reduced fracture risk.

Indications

• Hypercalcemia of malignancy (albumin-corrected serum calcium ≥ 12 mg/dL or 3.0 mmol/L)
• Multiple myeloma and bone metastases from solid tumors — prevention of skeletal-related events (pathologic fracture, spinal cord compression, radiation or surgery to bone)
• Osteoporosis — treatment in postmenopausal women, men, and glucocorticoid-induced osteoporosis
• Paget's disease of bone
• Prevention of postmenopausal osteoporosis (in select guidelines, though not universally FDA-labeled)

Dosage and Administration

Hypercalcemia of malignancy:

• 4 mg as a single intravenous infusion over at least 15 minutes. May be repeated if serum calcium does not normalize within 4–7 days.

Multiple myeloma / bone metastases:

• 4 mg IV over 15 minutes every 3–4 weeks. Concomitant oral calcium 500 mg and vitamin D 400 IU daily are recommended.

Osteoporosis (postmenopausal, male, glucocorticoid-induced):

• 5 mg IV over at least 15 minutes once yearly. Adequate calcium and vitamin D intake are required.

Paget's disease:

• 5 mg IV over at least 15 minutes. Retreatment may be considered after 6–12 months if response is inadequate.

Renal impairment (for bone metastasis/myeloma dosing):

• Dose adjustment based on baseline creatinine clearance (CrCl):
• CrCl > 60 mL/min: 4 mg
• CrCl 50–60: 3.5 mg
• CrCl 40–49: 3.3 mg
• CrCl 30–39: 3.0 mg
• CrCl < 30: not recommended
• For osteoporosis, Zometa is not recommended if CrCl < 35 mL/min or in patients with acute renal impairment.

Hepatic impairment: No dose adjustment required; zoledronic acid is not metabolized by the liver.

Pediatrics: Approved for severe osteogenesis imperfecta in some regions, but dosing is not standardized in the FDA label; use is generally off-label and should be guided by a specialist.

Geriatrics: No specific dose adjustment beyond renal function assessment.

Pregnancy: Contraindicated; bisphosphonates may cause fetal skeletal abnormalities.

Pharmacokinetics

• Absorption: Not orally bioavailable; administered intravenously.
• Distribution: Rapidly distributes to bone; plasma protein binding is approximately 22–43%. Volume of distribution is about 6–7 L.
• Metabolism: No significant hepatic metabolism; does not involve CYP450 enzymes.
• Elimination: Excreted unchanged by the kidneys via glomerular filtration and active tubular secretion. Renal clearance is approximately 60–70 mL/min.
• Half-life: Terminal half-life is prolonged (approximately 146 hours to several days in plasma, with a bone retention half-life of months to years). Clinical effect persists long after drug is no longer detectable in plasma.

Contraindications

• Hypersensitivity to zoledronic acid or any component of the formulation
• Hypocalcemia (must be corrected prior to initiation)
• Pregnancy (based on animal reproductive toxicity data)
• Severe renal impairment (CrCl < 30 mL/min for oncology indications; < 35 mL/min for osteoporosis)
• Patients with acute renal impairment due to increased risk of renal failure

Warnings and Precautions

• Renal toxicity: Zoledronic acid can cause acute renal failure, particularly in patients with pre-existing renal impairment, dehydration, or concurrent nephrotoxic drugs. Serum creatinine should be measured before each dose. Doses should not exceed 4 mg and infusion time should be at least 15 minutes.
• Osteonecrosis of the jaw (ONJ): Risk is increased with longer duration of therapy, poor oral hygiene, invasive dental procedures, and concomitant corticosteroids or antiangiogenic agents. A dental exam is recommended before starting therapy in patients with risk factors.
• Atypical femoral fractures: Rare, subtrochanteric and diaphyseal femoral fractures have been reported with prolonged bisphosphonate use. Evaluate patients presenting with thigh or groin pain for incomplete fractures.
• Hypocalcemia: Pre-existing hypocalcemia and vitamin D deficiency must be corrected before treatment. Monitor calcium, magnesium, and phosphate levels.
• Acute phase reaction: Flu-like symptoms (fever, myalgia, arthralgia) commonly occur within 24–72 hours after the first infusion, especially in osteoporosis patients. Symptoms typically resolve within days and are less frequent with subsequent doses.
• Ocular inflammation: Uveitis, scleritis, and conjunctivitis have been reported; discontinue if symptoms occur.
• Asthenia and electrolyte disturbances: Monitor for hypophosphatemia, hypomagnesemia, and hypokalemia, especially in oncology patients.

Drug Interactions

• Aminoglycosides: Additive hypocalcemia and renal toxicity; avoid concurrent use if possible.
• Loop diuretics: May worsen hypocalcemia and renal impairment; use with caution.
• Nephrotoxic drugs (e.g., NSAIDs, calcineurin inhibitors, cisplatin): Increased risk of renal dysfunction; monitor renal function closely.
• Thalidomide and antiangiogenic agents (e.g., bevacizumab, sunitinib): Increased risk of osteonecrosis of the jaw.
• Other bisphosphonates: Concomitant use is not recommended due to additive toxicity and lack of additional benefit.

Adverse Effects

Common (≥ 10%):

• Fever and flu-like symptoms (acute phase reaction)
• Myalgia, arthralgia, bone pain
• Nausea, vomiting, diarrhea
• Hypophosphatemia, hypocalcemia
• Headache

Serious/Rare:

• Acute renal failure
• Osteonecrosis of the jaw
• Atypical femoral fractures
• Severe musculoskeletal pain (debilitating, sometimes incapacitating)
• Atrial fibrillation (reported in some osteoporosis trials; causality not firmly established)
• Ocular inflammation (uveitis, scleritis)
• Anaphylaxis (rare)
• Hypomagnesemia, hypokalemia

Monitoring Parameters

• Serum creatinine before each dose; reassess renal function if decline occurs
• Serum calcium, phosphate, magnesium — baseline and periodic, especially in oncology patients
• Vitamin D status — correct deficiency before initiating therapy
• Dental examination — before starting therapy in patients with risk factors for ONJ
• Bone mineral density — for osteoporosis, repeat DXA every 1–2 years
• Bone turnover markers (e.g., NTX, P1NP) — optional, useful for assessing response
• Symptoms of thigh/groin pain — evaluate for atypical femoral fracture
• Hydration status — ensure adequate hydration before and after infusion

Patient Education

• Inform patients that Zometa is given as an intravenous infusion and requires regular dosing intervals (e.g., yearly for osteoporosis, monthly for oncology indications).
• Advise patients to maintain adequate intake of calcium and vitamin D (typically 1200 mg and 800–1000 IU daily, respectively) unless contraindicated.
• Emphasize good oral hygiene and regular dental check-ups; report any loose teeth, jaw pain, or non-healing oral sores immediately.
• Warn about the possibility of flu-like symptoms after the first infusion; these usually resolve within a few days and can be managed with acetaminophen or NSAIDs (if renal function is normal).
• Instruct patients to report new or unusual thigh or groin pain, as this may indicate an atypical fracture.
• Encourage adequate hydration before and after the infusion to reduce renal risk.
• Advise patients to inform all healthcare providers of their bisphosphonate use, especially before dental procedures or surgery.

Clinical Pearls

1. Zoledronic acid is the most potent bisphosphonate available; 4 mg IV is equivalent in efficacy to 90 mg pamidronate for hypercalcemia of malignancy.
2. Infusion time must be at least 15 minutes; faster infusion increases the risk of renal toxicity.
3. The acute phase reaction is most common after the first dose and can be mitigated with premedication (e.g., acetaminophen) and adequate hydration.
4. In oncology patients, zoledronic acid should be continued for up to 2 years, after which reassessment of ongoing benefit is recommended.
5. For osteoporosis, a single annual 5 mg dose provides fracture risk reduction comparable to weekly oral bisphosphonates, with improved adherence.
6. Always check renal function and serum calcium before each dose; hypocalcemia must be corrected prior to administration.

References

1. Novartis Pharmaceuticals Corporation. Zometa (zoledronic acid) injection, for intravenous use. Prescribing Information. FDA.gov. 2021.
2. U.S. Food and Drug Administration. Zometa (zoledronic acid) — Full Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021223s040lbl.pdf.
3. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 3.2024.
4. Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595-1622.
5. Ruggiero SL, Dodson TB, Aghaloo T, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw — 2022 update. J Oral Maxillofac Surg. 2022;80(5):920-943.
6. World Health Organization (WHO). Model List of Essential Medicines — 23rd List. Geneva: WHO; 2023.
7. Katzung BG, Vanderah TW. Basic and Clinical Pharmacology. 15th ed. McGraw-Hill Education; 2021.
8. Brunton LL, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th ed. McGraw-Hill Education; 2018.
9. Rosen HN. Bisphosphonate therapy for the treatment of osteoporosis. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. 2024.
10. Gralow JR, Biermann JS, Farooki A, et al. NCCN Task Force report: bone health in cancer care. J Natl Compr Canc Netw. 2013;11(Suppl 3):S1-S50.